EA033083B1 - Циклические соединения - Google Patents

Циклические соединения

Info

Publication number
EA033083B1
EA033083B1 EA201792469A EA201792469A EA033083B1 EA 033083 B1 EA033083 B1 EA 033083B1 EA 201792469 A EA201792469 A EA 201792469A EA 201792469 A EA201792469 A EA 201792469A EA 033083 B1 EA033083 B1 EA 033083B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemotherapy
relates
present
cyclic compounds
induced
Prior art date
Application number
EA201792469A
Other languages
English (en)
Russian (ru)
Other versions
EA201792469A1 (ru
Inventor
Тоситаке Кобаяси
Морихиса Сайтох
Ясуфуми Вада
Хироси Нара
Нобуюки Негоро
Тайсуке Катох
Масаси Ямасаки
Такахиро ТАНАКА
Наоми Китамото
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201792469A1 publication Critical patent/EA201792469A1/ru
Publication of EA033083B1 publication Critical patent/EA033083B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/12Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201792469A 2015-05-08 2016-05-06 Циклические соединения EA033083B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015095817 2015-05-08
PCT/JP2016/064204 WO2016182036A1 (en) 2015-05-08 2016-05-06 Cyclic compounds

Publications (2)

Publication Number Publication Date
EA201792469A1 EA201792469A1 (ru) 2018-06-29
EA033083B1 true EA033083B1 (ru) 2019-08-30

Family

ID=56132991

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792469A EA033083B1 (ru) 2015-05-08 2016-05-06 Циклические соединения

Country Status (11)

Country Link
US (3) US9611244B2 (https=)
EP (1) EP3294706B1 (https=)
JP (1) JP6718884B2 (https=)
CN (1) CN107835800B (https=)
AR (1) AR104539A1 (https=)
CA (1) CA2985325C (https=)
EA (1) EA033083B1 (https=)
ES (1) ES2772703T3 (https=)
TW (1) TW201704206A (https=)
UY (1) UY36675A (https=)
WO (1) WO2016182036A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107835800B (zh) * 2015-05-08 2019-11-26 武田药品工业株式会社 环状化合物
WO2018047888A1 (ja) 2016-09-09 2018-03-15 武田薬品工業株式会社 環状化合物
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214398C2 (ru) 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
DE60045033D1 (de) 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
JP2004002370A (ja) * 2002-04-08 2004-01-08 Takeda Chem Ind Ltd 重症セプシス予防治療剤
KR101327610B1 (ko) 2005-09-14 2013-11-12 다이이찌 산쿄 가부시키가이샤 치환 시클로알켄 유도체
JP2008260760A (ja) 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
CN107835800B (zh) * 2015-05-08 2019-11-26 武田药品工业株式会社 环状化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent

Also Published As

Publication number Publication date
CN107835800B (zh) 2019-11-26
AR104539A1 (es) 2017-07-26
EA201792469A1 (ru) 2018-06-29
EP3294706A1 (en) 2018-03-21
TW201704206A (zh) 2017-02-01
CN107835800A (zh) 2018-03-23
US20160326102A1 (en) 2016-11-10
CA2985325A1 (en) 2016-11-17
JP6718884B2 (ja) 2020-07-08
CA2985325C (en) 2023-09-26
US20170066737A1 (en) 2017-03-09
WO2016182036A1 (en) 2016-11-17
BR112017023818A2 (pt) 2018-07-31
UY36675A (es) 2016-12-30
US9828357B2 (en) 2017-11-28
JP2018516875A (ja) 2018-06-28
US9533966B2 (en) 2017-01-03
US20160326133A1 (en) 2016-11-10
ES2772703T3 (es) 2020-07-08
US9611244B2 (en) 2017-04-04
EP3294706B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
SA518391624B1 (ar) Ror- منظمات جاما
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
PH12019501811A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MY197561A (en) Composition for increasing expression of pgc-1?
EA033083B1 (ru) Циклические соединения
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX388592B (es) Compuestos y metodos terapeuticos.
UA117154C2 (uk) Антагоністи s1p3
WO2015001541A3 (en) Pharmaceutical film composition
PH12016502568A1 (en) Novel heterocyclic compound
MX2016008968A (es) Compuestos organicos.
MY197042A (en) Compounds
PH12017501336A1 (en) Preventive and/or therapeutic agent of immune disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM